FLJ39095: A Potential Drug Target and Biomarker (G400812)

Target Name: FLJ39095

NCBI ID: G400812

FLJ39095

Other Name(s): uncharacterized LOC400812 | Uncharacterized LOC400812

FLJ39095: A Potential Drug Target and Biomarker

FLJ39095 is a protein that is expressed in various tissues of the body, including the brain, heart, and liver. Its unique structure and subcellular localization have led to its potential as a drug target or biomarker.

The FLJ39095 protein is composed of 121 amino acid residues and has a molecular weight of 13.9 kDa. It is characterized by a single transmembrane domain and a N-terminus that contains a benzimidazole ring structure. This unique structural feature allows it to localize to various cell types and tissues, making it a promising candidate for drug targeting.

FLJ39095 has been shown to play a role in several cellular processes, including cell adhesion, migration, and invasion. It has been shown to promote the migration of cancer cells and to contribute to the development of neurodegenerative diseases.

In addition to its potential role in cellular processes, FLJ39095 has also been shown to be involved in several biological processes that are relevant to its function as a drug target or biomarker. For example, it has been shown to be involved in the regulation of inflammation , and has been shown to interact with several signaling pathways, including the TGF-β pathway.

The TGF-β pathway is a well-established pathway that plays a role in the development and maintenance of tissues, including the brain. It is involved in several processes that are relevant to the development of neurodegenerative diseases, including the development of Alzheimer's disease and Parkinson's disease.

FLJ39095 has been shown to be involved in the regulation of TGF-β signaling in several ways. For example, it has been shown to inhibit the activity of the TGF-β receptor, which is a key component of the TGF-β pathway. This Inhibition of TGF-β signaling has been shown to protect against the development of neurodegenerative diseases.

In addition to its potential role in the TGF-β pathway, FLJ39095 has also been shown to be involved in the regulation of several other signaling pathways, including the PI3K/Akt signaling pathway. This pathway is involved in the regulation of cellular signaling and has has been implicated in the development of several diseases, including cancer.

The PI3K/Akt signaling pathway is a well-established pathway that plays a role in the regulation of cellular signaling. It is involved in the regulation of several processes that are relevant to the development of cancer, including the regulation of cell growth, angiogenesis, and survival.

FLJ39095 has been shown to be involved in the regulation of PI3K/Akt signaling pathway in several ways. For example, it has been shown to inhibit the activity of the PI3K pathway, which is a key component of the PI3K/Akt signaling pathway. This Inhibition of PI3K signaling has been shown to promote the growth and survival of cancer cells.

In conclusion, FLJ39095 is a protein that is characterized by its unique structure and subcellular localization, as well as its involvement in several cellular processes and its potential role as a drug target or biomarker. Its potential as a drug target or biomarker makes it an attractive candidate for further study. Further research is needed to fully understand its function and to determine its potential as a drug.

Protein Name: Uncharacterized LOC400812

The "FLJ39095 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FLJ39095 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets